Orthopedic stem cell therapy in Tijuana, México.

Orthopedic regenerative therapy at TrueCell is built around four classes of biologic, calibrated to the joint, the disease stage, and the patient. Nothing on this page is a default protocol. Each is a tool, and the right tool depends on what we find when we examine you.

Wharton's jelly UC-MSCs, the workhorse

Allogeneic mesenchymal stem cells from screened, consented umbilical-cord donations. Cells are cultured and viability-verified in our ISO-accredited laboratory before every infusion. UC-MSCs work primarily through paracrine signaling. Secretion of immunomodulatory cytokines, growth factors, and exosomes that recalibrate the joint environment toward homeostasis.^[1] They are the most-studied biologic in our orthopedic catalogue and the basis of most single-joint protocols. Available doses range from 20–30M cells (mild joint disease) to 40–60M (moderate) to 100M (high-dose AVN, multi-site IV).

Muse cells, the homing subset

Multilineage-differentiating stress-enduring (Muse) cells are a distinct subset within the broader MSC population, originally characterized by Kuroda and Dezawa in 2010.^[6] They have stress-tolerance and homing characteristics that distinguish them from conventional MSCs, particularly the ability to migrate selectively to sites of injury after intravenous administration. We use Muse cells in two settings: IV homing (1.5×10⁷ standard or 3.0×10⁷ high-dose) and direct injection at specific anatomical targets.

Exosomes, cell-free signaling

Exosomes are small extracellular vesicles secreted by cells, carrying a cargo of microRNAs, proteins, and lipids that mediate intercellular communication. They are smaller, faster-acting, and less immunogenic than whole cells. Useful as adjuncts where local signaling needs amplification (intradiscal protocols, post-procedure inflammation modulation) or in patients for whom whole-cell infusion is not appropriate.

Platelet-rich plasma (PRP), autologous growth factors

PRP is a concentration of your own platelets prepared from a same-day blood draw. It delivers a burst of growth factors (PDGF, TGF-β, VEGF, IGF-1) locally. PRP is fast, autologous, and particularly useful in tendinopathic indications. Rotator cuff, lateral epicondylitis, plantar fasciitis. Where local growth-factor concentration appears to compound benefit. Combination protocols (UC-MSC + PRP) are common in our orthopedic formulary.^[12]

An honest, head-to-head comparison of regenerative therapy against the alternatives most patients have already tried, or are weighing.

Stem cell therapy vs. cortisone

Cortisone (intra-articular corticosteroid) is fast-acting, cheap, and widely available. It produces meaningful pain reduction within days and is the most common second-line intervention for joint pain. The tradeoff: cortisone is purely symptomatic. It does not change the joint's underlying tissue trajectory, and a 2017 randomized trial in the Journal of the American Medical Association demonstrated that repeated triamcinolone injections were associated with measurable cartilage volume loss over two years compared to saline.^[4] MSC therapy works in the opposite direction biologically. Rather than suppressing the inflammatory response, it recalibrates the cellular signaling toward a healing rather than degrading state. The benefit develops more slowly (weeks rather than days) and lasts longer (12 months rather than weeks-to-months).

Stem cell therapy vs. hyaluronic acid (viscosupplementation)

Hyaluronic acid injections lubricate the joint and may modulate inflammation modestly. Multiple randomized controlled trials have now compared MSC therapy directly against hyaluronic acid in knee OA and reported greater and longer-lasting pain reduction and functional improvement with MSCs. The head-to-head design is one of the strongest signals in the published literature.^[2][5]

Stem cell therapy vs. PRP

PRP and MSC therapy are not mutually exclusive. Many of our orthopedic protocols use both. PRP is autologous, fast to prepare, and particularly effective in tendinopathy where a local growth-factor burst supports tendon remodeling. MSC therapy adds sustained paracrine signaling over weeks and is the more powerful option for cartilage and synovium. In direct comparisons for knee OA, MSC therapy has tended to outperform PRP at longer follow-up; in pure tendinopathy, the data is closer. Combination protocols often beat either monotherapy.^[12]

Stem cell therapy vs. joint replacement (arthroplasty)

For end-stage, bone-on-bone arthritis (Kellgren-Lawrence grade 4), joint replacement remains the gold standard for durable pain relief and functional restoration. Modern total knee and total hip arthroplasty produce excellent 15–20 year results in appropriately selected patients. MSC therapy is not a substitute for replacement at end-stage disease. We will tell you so during the consult. Where MSC therapy fits is earlier in the disease arc, in patients with KL 1–3 osteoarthritis who still have years of native joint function to preserve and where the surgical alternative would be premature. The honest framing: MSC therapy can buy time, defer surgery, and improve quality of life in the meantime. Not replace surgery when it is genuinely indicated.

Stem cell therapy vs. arthroscopy

Arthroscopic surgery for degenerative meniscus tears and degenerative joint pathology has been the subject of multiple high-profile randomized trials over the past decade, with several reporting that the procedure produces little benefit over sham surgery in degenerative cases. MSC therapy is a less-invasive alternative for degenerative meniscus pathology, post-meniscectomy degeneration, and post-arthroscopy residual symptoms. Acute mechanical pathology (locking, large displaced tears, free fragments) often still requires arthroscopy. We refer those cases.

Stem cell therapy vs. spinal fusion

For axial low back pain from disc degeneration, lumbar fusion is an irreversible procedure with mixed long-term outcomes. Particularly for adjacent-segment disease that develops above and below the fusion. Pettine et al. demonstrated meaningful pain reduction at 12 months following intradiscal cell injection in carefully selected patients, suggesting an alternative pathway for patients who would otherwise be heading toward fusion.^[11] The intradiscal protocol is not for every back pain patient. Selection matters more in the spine than anywhere else in the orthopedic catalogue.

The medical-tourism stem-cell market in México and globally has grown faster than its scientific evidence base. Which means a lot of clinics are offering protocols that overstate what the literature actually supports. We aim to be the antidote to that.

Physician-led, not sales-led

Every protocol is prescribed by a board-certified physician after reviewing your imaging and history. Dr. Hans Ruiz Serna, certified by the Mexican Orthopedic Council, traumatologist and orthopedic surgeon, serves as Director of Orthopedics. He has performed over 2,000 surgeries and led complex cases at Hospital General Regional IMSS, Premier Medical Center, and Hospital Blue. Patient-facing decisions are physician decisions, not concierge decisions.

Our own ISO-accredited cell laboratory

Wharton's jelly UC-MSCs and Muse cells are prepared in-house, with viability and identity verification performed before every infusion. We do not source unverified cell products from third-party labs.

Honest candidacy assessment

If the physician determines that joint replacement, surgical repair, or rheumatology referral is the better answer for your case, we will tell you so. The consultation is complimentary; there is no incentive to push a protocol on someone for whom it is not appropriate.

Peer-reviewed evidence base

Every therapeutic claim on this page traces back to a numbered citation linking to the source paper on PubMed. We will not show you a "97% success rate" infographic without an underlying study you can read for yourself. Where the published evidence is strong, we say so. Where it is still developing, we say that too.

Concierge for international patients

Twenty minutes from the San Diego border. Door-to-door pickup from your San Diego hotel or the airport. Bilingual support throughout. Lodging coordination at preferred rates. Most international patients arrive on day zero, are treated on day one, and fly home on day two or three.

Transparent regulation

UC-MSC therapy at TrueCell is regulated by Mexico's COFEPRIS, the federal health regulator, and is not FDA-approved in the United States. We discuss the regulatory landscape in writing during informed consent. No claims of FDA endorsement, and no implication that the protocols are something they are not.

Across the orthopedic catalogue, the strongest published outcomes are in patients with early to moderate joint disease. Kellgren-Lawrence grades 1 through 3 for OA, partial-thickness rather than full-thickness tendon involvement, and pre-collapse rather than post-collapse avascular necrosis.^[1] These are the patients whose joints still have something worth preserving and whose surgical alternatives are morbid relative to the disease.

End-stage disease (bone-on-bone OA, complete tendon ruptures, post-collapse AVN) is generally better served by surgical reconstruction or replacement. We will tell you so during the consult if that is the right answer.

To produce an honest candidacy assessment we need recent imaging (MRI within 12–18 months ideal; X-ray minimum), a current medication list, recent labs, and a complete history. The consult itself is complimentary.

The questions every patient asks, and the answers we actually give. If your question isn't here, our concierge will reply within one business day.